Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Compass Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 180.09M shares outstanding
USCompass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials.
The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1.
The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Leadership
Arjun Prasad, M.B.A., M.P.H.
Chief Commercial Officer
Barry Shin, J.D., M.B.A.
Chief Financial Officer
Bing Gong, Ph.D.
Chief Scientific Officer
Carl L. Gordon, Ph.D., C.F.A.
Chairman of the Board
Employees
39
Country
US
Sector
Healthcare
Website
compasstherapeutics.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Lerner Neil | Chief Accounting Officer | Purchase | 20.0K | $18.4K | Oct 1, 2026 |
| Lerner Neil | Chief Accounting Officer | Purchase | 2.5K | $2.8K | Sep 24, 2026 |
 Anderman Jonathan | General Counsel | Grant/Award | 25.0K | $47.3K | Apr 29, 2026 |
| Lerner Neil | Chief Accounting Officer | Purchase | 15.0K | $28.4K | Apr 29, 2026 |
| Lerner Neil | Chief Accounting Officer | Grant/Award | 15.0K | $28.4K | Apr 29, 2026 |
| Anderman Jonathan | General Counsel | Purchase | 25.0K | $47.3K | Apr 29, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 18.0M | 10.0% | 13F |
ORBIMED ADVISORS LLC | 15.2M | 8.5% | 13F |
MONTANOVA CAPITAL, LLC | 14.1M | 7.8% | 13F |
BlackRock, Inc. | 11.3M | 6.3% | 13F |
STATE STREET CORP | 10.0M | 5.5% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jan 2026 | 9.3M | 5.1% | 13G |
Enavate Sciences GP, LLC | 7.8M | 4.3% | 13F |
BVF INC/IL · joint filing· may incl. warrants· filed May 2026 | 7.8M | 4.3% | 13G |
Vivo Capital, LLC | 7.8M | 4.3% | 13F |
 Schuetz Thomas J. CHIEF EXECUTIVE OFFICER, Director | 6.6M | 3.7% | FORM 4 |
Insiders
- Lerner NeilChief Accounting Officer
- Anderman JonathanGeneral Counsel
- Schuetz Thomas J.CHIEF EXECUTIVE OFFICER
- Shin BarryCFO
- Sirard CynthiaChief Medical Officer
- LINDAHL RICHARD SDirector
- Chiniara EllenDirector
- GRAY MARY ANNDirector
- Boylan James PDirector
- GORDON CARL LDirector
based on 180.09M shares outstanding
US30d Avg
5.49M
60d Avg
4.95M
90d Avg
4.34M